anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, chemical- pharmaceutical industry, pharmacy. SUBSTANCE: invention proposes sanguiritrin-base an antibacterial agent of the general resorptive effect as tablets covered by enterosoluble envelope. Sanguiritrine enterosoluble tablets are prescribed for children and adults by oral route for treatment of dysbacteriosis and intestinal infections (dysentery, salmonellosis, food toxic infections, acute infectious gastroenteritis, acute infectious enterocolitis) and in reconvalescent germ carrier accompanying different infectious inflammatory processes. Invention provides elimination of by-side effects (nausea, vomiting, diarrhea). EFFECT: enhanced effectiveness of drug. 15 cl, 6 ex
1. A pharmaceutical formulation comprising an osmotic amount of polyethylene glycol (PEG) 3350, or PEG 4000, and a pharmaceutically acceptable effervescent coupling system. 2. The formulation according to Claim 1 wherein the effervescent couple comprises about 10 to about 30% of the total weight of the formulation. 3. The formulation according to Claim 1 wherein the effervescent couple comprises an acid component selected from citric acid, tartaric acid, adipic acid, fumaric acid, malic acid, or acid salts thereof, or mixtures thereof. 4. The formulation according to Claim 1 wherein the effervescent couple comprises an alkaline component selected from sodium, potassium or calcium (bi) carbonates or sodium glycine carbonate. 5. The formulation according to any one of Claims 1 to 4 which further comprises one or more flavoring, colouring or sweetening agents. 6. The formulation according to Claim 1 wherein the PEG is present in an amount of 7.5 to 30 grams per unit dose. 7. The formulation according to Claim 1 wherein the PEG is present in an amount of 10 to 20 grams per unit dose. 8. A method of treating constipation in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a formulation according to any of claims 1 to 7. 9. A method of treating fecal impaction in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a formulation according to any of claims 1 to 7. 10. A formulation according to any one of claims 1 to 6 wherein the formulation is in a unit dose sachet.
People with human immunodeficiency virus (HIV) commonly use cannabis but whether cannabis affects the antiretroviral therapy (ART) that treats HIV is not well known. Cannabis can inhibit the activity of enzymes that metabolize and eliminate ART drugs from the body, which could result in higher concentrations of ART drugs in the body. Cannabis may also affect the distribution of ART drugs into the brain, which could have both beneficial (e.g., better HIV control) and detrimental (e.g., toxicity) effects. The effects of cannabis may are likely influenced by factors like how much is used (e.g., light vs. heavy use) and the route of use (e.g., smoked vs. ingested). This study will address whether cannabis affects ART concentrations in blood and cerebrospinal fluid as well as mood, and thinking. The project will have two phases. Phase 1 is an observational study, in which 120 people will be assessed once to evaluate the effects of chronic cannabis use on ART drug concentrations, mood, and thinking. In Phase 2, the study will administer cannabis (or placebo) to 40 people to examine its acute effects on ART drug concentrations.
Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will continue on ibodutant 10 mg for additional 28 weeks of treatment via mock-re-randomisation at week 25 .
The embodiment of the invention relates to an intelligent electrocardio-analysis device, which comprises: microprocessor, storage module group, memory module, credible module, deep learning module, input and output module group, data bus, work indicator, power interface, printed circuit board. The storage module group comprises a first storage module and a second storage module. The input and output module group comprises a USB and UART input and output module, and the transmission data of the USB input and output module uses NDIS protocol. The deep learning module supports two deep learning calculation models of electrocardio interference classification and heart beat classification. The intelligent electrocardio analysis device provided by the invention supports a USB network interface and can be seamlessly connected with different operating system peripherals; and the deep learning is supported, and two deep learning calculation models of interference classification and heart beat classification are provided for electrocardio data analysis. The device can effectively perform directional analysis on the electrocardio data in real time.
Participants in this group will receive the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy). In order to balance the number of treatment hours between arms, this group will receive extra time of Conventional Treatment during 1 month.
Radiotherapy (RT) plays a key role in the tumour microenvironment (TME), impacting the immune response via cellular and humoral immunity. RT can induce local immunity to modify the TME. It can stimulate dendritic cell maturation and T-cell infiltration. Moreover, B cells, macrophages and other immune cells may also be affected. Tertiary lymphoid structure (TLS) is a unique structure within the TME and a class of aggregates containing T cells, B cells and other immune cells. The maturation of TLS is determined by the presence of mature dendritic cells, the density of TLS is determined by the number of immune cells. TLS maturation and density both affect the antitumour immune response in the TME. This review summarized the recent research on the impact and the role of RT on TLS, including the changes of TLS components and formation conditions and the mechanism of how RT affects TLS and transforms the TME. RT may promote TLS maturation and density to modify the TME regarding enhanced antitumour immunity.
Background:Oral epithelial dysplasia (OED) is one of the common precancerous lesions among Chinese adults. To investigate the clinical predictive value of p16 methylation diagnostic reagents in the early diagnosis of oral cancer, the investigators carried out the prospective multi-center double-blind cohort study.

Methods:180 patients with histologically confirmed mild or moderate OED were included in the present study. The investigators using p16 methylation diagnostic reagents to analysis of the p16 methylation status in these patients. Building two follow-up queue by p16-methylated and p16-unmethylated. The Statistical analysis used SAS6.12 software. All P-values were two-sided. P\<0.05 was considered to test for statistical significance difference.
FIELD: medicine, therapy. SUBSTANCE: curative composition has N-acetylcysteine, artificial sweetening substance, for example, saccharin, cyclamates or their mixtures, thickening agent (carboxymethylcellulose sodium or hydroxypropylmethylcellulose or their mixture). Composition can contain aromatic substance and preserving agent also. Composition must has pH 5.0-8.0. Composition can be used at catarrhal diseases. EFFECT: improved properties of composition. 7 cl
The invention relates to a method for treating an overdosing with active substance dabigatran etexilate of formula I optionally in the form of the pharmaceutically acceptable salts thereof, comprising the administration of an effective amount of charcoal. The invention relates to a method for treating an overdosing with active substance dabigatran etexilate of formula I optionally in the form of the pharmaceutically acceptable salts thereof, comprising the administration of an effective amount of charcoal. A method for storing and retrieving data in a storage node of a data store and storage node of a data store, storing in main-memory at least one segment of a relational table is described. The storage node comprises at least one computational core running at least one scan thread each dedicated to the scanning of one of the at least one segment. The storage node is characterized in that the at least one scan thread uniquely, continuously and exhaustively scans the dedicated segment of the relational table. The storage node receives and processes batches of query and update operations for the at least one segment of the relational table. The query and update operations of a batch are re-indexed at beginning of each scan by the scan thread. Then, the indexed query and update operations of a batch are independently joined to data records of said segment that match with predicates of the indexed query and update operations so that the indexed query and update operations of a batch are progressively fulfilled whenever joined data records are retrieved by the scan thread while scanning said segment. This allows maximizing the sharing and access of data records in main- memory between query and update operations of a batch.
Arm 1a (N=5) to receive 16 micrograms Pfs25M on D0, D28. Arm 1b (N=5) to receive 47 micrograms Pfs25M on D0, D28.
Inhaled bronchodilators, such as beta 2 agonists and anticholinergics, and inhaled corticosteroids are the mainstays of therapy in patients diagnosed with COPD. Anticholinergic bronchodilators or long acting muscarinic receptor antagonists function by blocking endogenous airway smooth muscle cholinergic tone. Treatment with anticholinergics has been shown to significantly improve forced expiratory volume in 1 second (FEV1), resting and dynamic lung hyperinflation, symptoms, and exercise capacity in patients with COPD. Currently tiotropium is the only approved long acting muscarinic antagonist available for treatment of COPD.

This is a multicenter, randomized, double-blind, placebo controlled, three way crossover, incomplete block study to evaluate 4 doses of GSK573719 inhaled once daily and 2 doses of GSK573719 inhaled twice daily over 7 days in patients with COPD. Tiotropium will be included as an open label active comparator. A placebo treatment will be included to evaluate treatment effect of each GSK573719 dose. Pharmacokinetic profiles of GSK573719 will also be determined. Each eligible subject will receive a sequence of 3 of 8 potential treatments for a total of 3 treatment periods per subject. There will be 7 clinic visits, during three of which 24 hour serial spirometry will be performed. The total duration of subject participation is approximately 9 weeks.
Retrospective data collection will be carried out from the medical records of the participants included in the study. Will be held description of the epidemiological profile and pathological staging of diffuse large B-cell lymphoma conditions (DLBCL/LDGCB), imaging profiling, together with first-line treatment used in subgroups of germinal center or activated B-cell, in patients followed in Brazilian reference cancer treatment centers, within the last 6 years (between 2017 and 2022).
Patients receive modified FOLFOX 6 or CAPOX as in arm I. Treatment repeats every 14 days for 12 courses (6 months)or regarding CAPOX every 21 days for 8 courses (6 month).
The present invention discloses Chinese traditional medicine for treating the congenital heart disease of a baby. The formula of the present invention has effective content: 40 grams of astragalus roots, 30 grams of pilose asiabell roots, 30 grams of pseudostellaria roots, 30 grams of lilyturf roots, 25 grams of baked date kernels, 40 grams of arborvitae seeds, 20 grams of Chinese angelica, 15 grams of hemlock parsley, 20 grams of red peony roots, 20 grams of rehmannia roots, 30 grams of red sage roots, 30 grams of longan aril, 20 grams of pulp of dogwood fruit, 10 grams of radix polygalae preparata, 20 grams of baked white atractylodes rhizomes, 40 grams of chicken blood collection, 20 grams of hairy holly roots, 10 grams of coptis roots, 15 grams of green tangerine peels, 20 grams of trichlosanthes fruit, 20 grams of bulbus allii macrostemi, 10 grams of raw cattail pollen, 15 grams of rosewood, 10 grams of aucklandia roots, 10 grams of roasted liquorice and 5 grams of donkey-hide gelatin (which is well dissolved to put into the medicine). The present invention has the preparation method that the medicine is boiled after the medicine is soaked with boiling water for one hour, and the medicine is filtered after the medicine is fried by slow fire for 30 minutes after water is boiled. Donkey-hide gelatin is added into liquid medicine which is obtained to be blended, and the liquid medicine is taken thrice in morning, at noon and in evening. The Chinese traditional medicine can be ground into powder, and can be made into capsules to be taken. The traditional Chinese medicine of the present invention has the advantages of good curative effect, quick effect, radical cure and no rebound. An effective rate of the traditional Chinese medicine reaches 98%.
Patients in group 2 already use a potentially relevant DOAC-SMI combination or already use an SMI and start with a DOAC. In this group, blood samples are taken after the start of concomittant use of the DOAC-SMI combination.
Autophagy (AU) and programmed cell death (PCD) are dynamically regulated during tomato fruit defense against Botrytis cinerea, which are also manipulated by pathogenic effectors to promote colonization. Present study demonstrated that the enhanced defense induced by transient inhibition on AU by hydroxychloroquine (HCQ) facilitated the restriction of B. cinerea lesion on postharvest tomato. Pre-treatment of 2 mM (16.08 ± 3.42 cm at 7 d) and 6 mM (7.80 ± 2.39 cm at 7 d) HCQ inhibited the lesion development of B. cinerea compared with Mock treatment (50.02 ± 7.69 cm at 7 d). Transient inhibition of AU induced expression of fungal defense and transcriptional regulation related genes, but attenuated reactive oxygen species (ROS) burst gene expression. The ROS-induced PCD was compromised by HCQ with promoted ROS scavenging. The transient pre-treatment of HCQ slightly inhibited AU which triggered the feedback loop that enhanced the autophagic activity defensing against B. cinerea infection.
The present invention relates to a nanometer selenium of chitin, which is a compound comprising chitin and red nanometer selenium. The compound is prepared by the reaction of the chitin comprising chitosan, water-soluble chitosan and chitosan oligosaccharide and a selenium compound. The structure, the composition, the property of the nanometer selenium of chitin are comparatively researched by an infrared spectrometer, an ultraviolet spectrometer, a mass spectrometer, a transmission electron microscope, etc. The red nanometer selenium is absorbed and wrapped by the chitin to form a stable particle, and the microstructure is in a spherical or fractal structure. The structure and the property of the chitin are unchanged. The nanometer selenium of chitin has the efficacy of immunological regulation, ageing resistance of the nanometer selenium and the chitin, face beautification, cancer prevention, cardiovascular disease prevention, etc. The nanometer selenium of chitin has wide application prospects in the fields of medicine, health protection, food, etc. The preparation method is simple and practical at normal temperature and pressure, and the nanometer selenium of chitin is operated and controlled conveniently, and is suitable for industrial production.
The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor. The first session will last 60 minutes and the content will include psychoeducation about the importance of sleep, sleep guidelines and target setting, and basic sleep hygiene. Participants in this condition will receive hardcopy weekly daily diary worksheets, and receive an online version of the sleep daily diary every morning to complete via text messaging. Sessions 2-4 will be between 15-30 minutes where Dr. Wu or a trained counselor will review the sleep diary, problem solve barriers to weekly goals, and sleep promoting behaviors will be reinforced. Material that would be covered during a missed session will be included in the next session the participant attends.
BACKGROUND: Isolated fallopian tube torsion (IFTT) is very rare gynecological emergency in pediatric population. Our objective is to assess treatment options and discuss outcome of a cohort of IFTT with a focus on the association between IFTT and hydrosalpinx (HSX).
METHODS: A retrospective review was conducted. Pediatric patients with IFTT operated in the same center were included.
RESULTS: Seventeen girls (aged: 11-16 years) were managed for acute abdominal pain between 2008 and 2018, with intraoperative diagnosis of IFTT. All patients underwent laparoscopic exploration, with laparoscopically fallopian tube detorsion in all patients. Based on the association of IFTT with HSX after fallopian tube detorsion, patients were divided into 2 groups: group 1 (IFTT without HSX; 12 girls) and group 2 (IFTT with HSX; 5 girls). During the same surgery, complementary surgical procedures were done. In group 1: salpingectomies (4), partial salpingectomies (2) and cystectomies (6) were done. In group 2: salpingectomy (1), salpingotomy (1), and cyst ablation (1). The treatment was called conservative when the tube was preserved.Follow-up was uneventful in group 1. In group 2, for all patients with initial fallopian tube preservation, further surgical procedures were necessary (1-4 surgeries/patient), and, finally, another 3 patients required salpingectomy.
CONCLUSIONS: Conservative treatment with tube preservation of IFTT without HSX appeared to be beneficial compared to those with HSX, with no recurrence of torsion or symptoms during the follow-up. However, the same conservative treatment was not sufficiently effective for IFTT with HSX and required further procedures due to recurrence of torsion.
LEVEL OF EVIDENCE: IV.
Risk Summary

There are no available human data for the use of VYZULTA during pregnancy to inform any drug associated risks.

Latanoprostene bunod has caused miscarriages, abortion, and fetal harm in rabbits. Latanoprostene bunod was shown to be abortifacient and teratogenic when administered intravenously (IV) to pregnant rabbits at exposures ≥ 0.28 times the clinical dose. Doses ≥ 20 mcg/kg/day (23 times the clinical dose) produced 100% embryofetal lethality. Structural abnormalities observed in rabbit fetuses included anomalies of the great vessels and aortic arch vessels, domed head, sternebral and vertebral skeletal anomalies, limb hyperextension and malrotation, abdominal distension and edema. Latanoprostene bunod was not teratogenic in the rat when administered IV at 150 mcg/kg/day (87 times the clinical dose) [see Data]. 

The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies.

Data

Animal Data

Embryofetal studies were conducted in pregnant rabbits administered latanoprostene bunod daily by intravenous injection on gestation days 7 through 19, to target the period of organogenesis. The doses administered ranged from 0.24 to 80 mcg/kg/day. Abortion occurred at doses ≥ 0.24 mcg/kg/day latanoprostene bunod (0.28 times the clinical dose, on a body surface area basis, assuming 100% absorption). Embryofetal lethality (resorption) was increased in latanoprostene bunod treatment groups, as evidenced by increases in early resorptions at doses ≥ 0.24 mcg/kg/day and late resorptions at doses ≥ 6 mcg/kg/day (approximately 7 times the clinical dose). No fetuses survived in any rabbit pregnancy at doses of 20 mcg/kg/day (23 times the clinical dose) or greater. Latanoprostene bunod produced structural abnormalities at doses ≥ 0.24 mcg/kg/day (0.28 times the clinical dose). Malformations included anomalies of sternum, coarctation of the aorta with pulmonary trunk dilation, retroesophageal subclavian artery with absent brachiocephalic artery, domed head, forepaw hyperextension and hindlimb malrotation, abdominal distention/edema, and missing/fused caudal vertebrae.

An embryofetal study was conducted in pregnant rats administered latanoprostene bunod daily by intravenous injection on gestation days 7 through 17, to target the period of organogenesis. The doses administered ranged from 150 to 1500 mcg/kg/day. Maternal toxicity was produced at 1500 mcg/kg/day (870 times the clinical dose, on a body surface area basis, assuming 100% absorption), as evidenced by reduced maternal weight gain. Embryofetal lethality (resorption and fetal death) and structural anomalies were produced at doses ≥ 300 mcg/kg/day (174 times the clinical dose). Malformations included anomalies of the sternum, domed head, forepaw hyperextension and hindlimb malrotation, vertebral anomalies and delayed ossification of distal limb bones. A no observed adverse effect level (NOAEL) was established at 150 mcg/kg/day (87 times the clinical dose) in this study.